Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors

Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors

Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant growth in revenue and subscriber numbers. Despite the rally, the company faces an ongoing challenge with GLP-1 drug shortages, a critical component in its expanding weight-loss solutions. Executives from Hims & Hers indicated that the scarcity of […]

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal

Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada’s esteemed specialty pharmaceutical giant. This collaboration aims at the commercialization of Liraglutide, a sophisticated drug-device formulation. This game-changing combination has been curated for the proficient treatment and management of challenges like Type 2 diabetes and […]

Biocon partners with Zentiva for European marketing of Liraglutide

Biocon partners with Zentiva for European marketing of Liraglutide

Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management of Type 2 diabetes as well as obesity. As per the terms of the agreement, the Indian pharma company will handle Liraglutide’s manufacturing and supply to Zentiva for the commercialization […]